University Hospital, Antwerp is recruiting patients for a PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for mesothelioma.
The trial, designated NCT05765084, aims to enroll up to 15 participants at 3 sites.
About the Study
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.
Treatment Approach
This trial uses a PD-L1 checkpoint inhibitor being studied in combination with other treatments.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: University Hospital, Antwerp
- Enrollment target: 15
- Status: RECRUITING
Why This Trial Matters
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening